FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1986014738> ?p ?o ?g. }

• W1986014738 endingPage "S58" @default.
• W1986014738 startingPage "S57" @default.
• W1986014738 abstract "Urokinase-type plasminogen activator (uPA) and PAIl, are involved in invasive phenotype of several tumors, and have been recently described in malignant gliomas. Expression and tissular localization of PAI2, as well as the clinical relevance of these proteases, need however to be investigated. In the present study, 42 patients with glioma were analyzed for expression of uPA, PAIl, and PAI2 (oligodendrocytoma (n = 2), gliomagrade I–II (n = 6), grade III (n = 6). and grade IV (n = 28). (1) Median cytosolic levels of uPA and PA11 as detennined by EUSA, were respectively 0.03 ng/mg protein (range 0.003–0.16) and 11.9 ng/mg protein (range 0.25–161.8). The highest levels of PAIl were found in grade IV tumors as compared to grades I–III (P < 0.001). Expression of uPA and PAIl was confinned by Northern blot and in situ hybridization which localized PAI1 predominantly around neoangiogenic foci, both in tumor and endothelial cells. (2) Expression of PAI2 antigen was heterogeneously distributed among tumors (median = 0.18 ng/mg protein, range 0.02–6.8) but was undetectable in control tissues. This data was confirmed by in situ hybridization. (3) Univariate analysis demonstrated that high levels of PAIl are associated with a shorter disease-free survival both for the overall population (P = 0.02), and the grades IV (P = 0.06). In grade IV gliomas, high levels of PAI2 are, in contrast, highly correlated to a better overall survival rate at 18 months (48% vs 0%, P = 0.015). Our preliminary results suggest that, in malignant gliomas, PAIl and PAI2 may be useful in the analysis of therapeutic protocols. Further studies should precise their biological role, in order to evaluate them as potential therapeutic target. Urokinase-type plasminogen activator (uPA) and PAIl, are involved in invasive phenotype of several tumors, and have been recently described in malignant gliomas. Expression and tissular localization of PAI2, as well as the clinical relevance of these proteases, need however to be investigated. In the present study, 42 patients with glioma were analyzed for expression of uPA, PAIl, and PAI2 (oligodendrocytoma (n = 2), gliomagrade I–II (n = 6), grade III (n = 6). and grade IV (n = 28). (1) Median cytosolic levels of uPA and PA11 as detennined by EUSA, were respectively 0.03 ng/mg protein (range 0.003–0.16) and 11.9 ng/mg protein (range 0.25–161.8). The highest levels of PAIl were found in grade IV tumors as compared to grades I–III (P < 0.001). Expression of uPA and PAIl was confinned by Northern blot and in situ hybridization which localized PAI1 predominantly around neoangiogenic foci, both in tumor and endothelial cells. (2) Expression of PAI2 antigen was heterogeneously distributed among tumors (median = 0.18 ng/mg protein, range 0.02–6.8) but was undetectable in control tissues. This data was confirmed by in situ hybridization. (3) Univariate analysis demonstrated that high levels of PAIl are associated with a shorter disease-free survival both for the overall population (P = 0.02), and the grades IV (P = 0.06). In grade IV gliomas, high levels of PAI2 are, in contrast, highly correlated to a better overall survival rate at 18 months (48% vs 0%, P = 0.015). Our preliminary results suggest that, in malignant gliomas, PAIl and PAI2 may be useful in the analysis of therapeutic protocols. Further studies should precise their biological role, in order to evaluate them as potential therapeutic target." @default.
• W1986014738 created "2016-06-24" @default.
• W1986014738 creator A5007576166 @default.
• W1986014738 creator A5009549690 @default.
• W1986014738 creator A5024598442 @default.
• W1986014738 creator A5042334675 @default.
• W1986014738 creator A5064835150 @default.
• W1986014738 creator A5067374804 @default.
• W1986014738 creator A5091903245 @default.
• W1986014738 date "1995-11-01" @default.
• W1986014738 modified "2023-09-26" @default.
• W1986014738 title "262 Low expression of plasminogen activator inhibitor (PAI) type I (PAI1) and high level of PAI type 2 (PAI2) are associated to a better outcome in gliomas" @default.
• W1986014738 doi "https://doi.org/10.1016/0959-8049(95)95520-g" @default.
• W1986014738 hasPublicationYear "1995" @default.
• W1986014738 type Work @default.
• W1986014738 sameAs 1986014738 @default.
• W1986014738 citedByCount "0" @default.
• W1986014738 crossrefType "journal-article" @default.
• W1986014738 hasAuthorship W1986014738A5007576166 @default.
• W1986014738 hasAuthorship W1986014738A5009549690 @default.
• W1986014738 hasAuthorship W1986014738A5024598442 @default.
• W1986014738 hasAuthorship W1986014738A5042334675 @default.
• W1986014738 hasAuthorship W1986014738A5064835150 @default.
• W1986014738 hasAuthorship W1986014738A5067374804 @default.
• W1986014738 hasAuthorship W1986014738A5091903245 @default.
• W1986014738 hasConcept C104317684 @default.
• W1986014738 hasConcept C126322002 @default.
• W1986014738 hasConcept C144301174 @default.
• W1986014738 hasConcept C150194340 @default.
• W1986014738 hasConcept C153911025 @default.
• W1986014738 hasConcept C185592680 @default.
• W1986014738 hasConcept C2776892390 @default.
• W1986014738 hasConcept C2778227246 @default.
• W1986014738 hasConcept C2779679481 @default.
• W1986014738 hasConcept C2908647359 @default.
• W1986014738 hasConcept C38180746 @default.
• W1986014738 hasConcept C502942594 @default.
• W1986014738 hasConcept C54355233 @default.
• W1986014738 hasConcept C71924100 @default.
• W1986014738 hasConcept C81439078 @default.
• W1986014738 hasConcept C86803240 @default.
• W1986014738 hasConcept C99454951 @default.
• W1986014738 hasConceptScore W1986014738C104317684 @default.
• W1986014738 hasConceptScore W1986014738C126322002 @default.
• W1986014738 hasConceptScore W1986014738C144301174 @default.
• W1986014738 hasConceptScore W1986014738C150194340 @default.
• W1986014738 hasConceptScore W1986014738C153911025 @default.
• W1986014738 hasConceptScore W1986014738C185592680 @default.
• W1986014738 hasConceptScore W1986014738C2776892390 @default.
• W1986014738 hasConceptScore W1986014738C2778227246 @default.
• W1986014738 hasConceptScore W1986014738C2779679481 @default.
• W1986014738 hasConceptScore W1986014738C2908647359 @default.
• W1986014738 hasConceptScore W1986014738C38180746 @default.
• W1986014738 hasConceptScore W1986014738C502942594 @default.
• W1986014738 hasConceptScore W1986014738C54355233 @default.
• W1986014738 hasConceptScore W1986014738C71924100 @default.
• W1986014738 hasConceptScore W1986014738C81439078 @default.
• W1986014738 hasConceptScore W1986014738C86803240 @default.
• W1986014738 hasConceptScore W1986014738C99454951 @default.
• W1986014738 hasLocation W19860147381 @default.
• W1986014738 hasOpenAccess W1986014738 @default.
• W1986014738 hasPrimaryLocation W19860147381 @default.
• W1986014738 hasRelatedWork W1542148298 @default.
• W1986014738 hasRelatedWork W1989114127 @default.
• W1986014738 hasRelatedWork W2016450706 @default.
• W1986014738 hasRelatedWork W2355221664 @default.
• W1986014738 hasRelatedWork W2361240968 @default.
• W1986014738 hasRelatedWork W2373928881 @default.
• W1986014738 hasRelatedWork W2375201474 @default.
• W1986014738 hasRelatedWork W2379951439 @default.
• W1986014738 hasRelatedWork W2380337528 @default.
• W1986014738 hasRelatedWork W3181383798 @default.
• W1986014738 hasVolume "31" @default.
• W1986014738 isParatext "false" @default.
• W1986014738 isRetracted "false" @default.
• W1986014738 magId "1986014738" @default.
• W1986014738 workType "article" @default.